|
| | 2',3',5'-Tri-O-acetyluridine Basic information |
| Product Name: | 2',3',5'-Tri-O-acetyluridine | | Synonyms: | 2'', 3'', 5''-TRIACETYLURIDINE (2'', 3'', 5''-TRI-O-ACETYLURIDINE);RG 2133;Tri-O-acetyl uridine;Vistonuridine;1-((2R,3R,4R,5R)-3,4-Diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)tetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione;2',3',5'-Tri-O-acetyl-rU;1-((2R,3R,4R,5R)-3,4-Diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)tetrahydrofuran-2-yl)pyrimid;ANTI-TAU(C-TERMINAL) antibody produced in rabbit | | CAS: | 4105-38-8 | | MF: | C15H18N2O9 | | MW: | 370.31 | | EINECS: | 223-881-5 | | Product Categories: | | | Mol File: | 4105-38-8.mol |  |
| | 2',3',5'-Tri-O-acetyluridine Chemical Properties |
| Melting point | 127.0 to 131.0 °C | | density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Chloroform (Slightly), Dichloromethane (Slightly), DMSO (Slightly) | | form | Solid | | pka | 9.39±0.10(Predicted) | | color | Off-White | | InChI | InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1 | | InChIKey | AUFUWRKPQLGTGF-QRMSVCKNSA-N | | SMILES | C(OC(=O)C)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@H](OC(=O)C)[C@@H]1OC(=O)C | | CAS DataBase Reference | 4105-38-8(CAS DataBase Reference) |
| Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29349990 |
| | 2',3',5'-Tri-O-acetyluridine Usage And Synthesis |
| Description | Uridine
triacetate is an orally available pro-drug of uridine approved by
the FDA for the treatment of the rare autosomal recessive
disorder called hereditary orotic aciduria. The drug was also
approved for treating overdose of two chemotherapies
(fluorouracil and capecitabine). Uridine triacetate was
developed by Wellstat Therapeutics and licensed to BTG. | | Chemical Properties | White or almost white crystalline powder | | Uses | 2’,3’,5’-Triacetyluridine is used in the treatment of Alzheimer’s disease in mice and provide neuroprotective effects. Shown to also decrease depressive symptoms and increases in brain pH bipolar patients. | | Definition |
ChEBI: Uridine triacetate is an acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. It has a role as a prodrug, a neuroprotective agent and an orphan drug. It is a member of uridines and an acetate ester.
| | Synthesis | Commercially available uridine (167) was treated with acetic
anhydride in the presence of catalytic boron trifluoride-etherate,
and the crude product was recrystallized from ethanol to give
uridine triacetate (XX) in 74-78% yield.
 |
| | 2',3',5'-Tri-O-acetyluridine Preparation Products And Raw materials |
|
